10-K: Abpro Holdings Faces Going Concern Doubts Amidst Restatement and Financial Weaknesses

Abpro Holdings' 10-K filing reveals a restatement of prior financials due to accounting errors, raising concerns about the company's ability to continue as a going concern and impacting investor confidence.

Summary

• Abpro Holdings, Inc. has filed its Form 10-K for the fiscal year ended December 31, 2024, which includes a restatement of previously issued financial statements for the periods ended September 30, 2024, December 31, 2023, and December 31, 2022.
• The restatement was due to the understatement of liabilities under one of its license agreements, increasing accrued expenses, total liabilities, and accumulated deficit by an estimated $3.3 million for each non-reliance period.
• Management has identified material weaknesses in its internal control over financial reporting related to the license agreement, which contributed to the restatement.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern due to ongoing operating losses and the need for additional financing.
• The company's net loss for 2024 was $7.2 million, compared to $11.7 million in 2023.
• As of April 15, 2025, there were 52,219,378 shares of common stock outstanding.
• The company expects to initiate clinical trials for ABP-102 in the first half of 2026 and in the second half of 2026 for ABP-201.
• The company has a worldwide strategic partnership with Celltrion for ABP-102 and a territorial partnership with Abpro Bio International for ABP-201.
• The company is in breach of the terms of its license agreement with MedImmune/AstraZeneca related to ABP-201.
• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (YA) for up to $50 million and a Forward Purchase Agreement with YA for up to 500,000 shares of common stock.
• The company entered into a Convertible Promissory Note for $3,000,000 with YA, issued with an 8% original issue discount.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a restatement, going concern doubts, and internal control weaknesses. While there are partnerships and potential capital raising, the overall tone is negative from an investment perspective.

Positives

• The company has partnerships with Celltrion and Abpro Bio International for the development and commercialization of its lead product candidates.
• The company expects to initiate clinical trials for ABP-102 and ABP-201 in 2026.
• The company has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (YA) for up to $50 million and a Forward Purchase Agreement with YA for up to 500,000 shares of common stock.
• The company entered into a Convertible Promissory Note for $3,000,000 with YA, issued with an 8% original issue discount.

Negatives

• Abpro Holdings restated its financial statements for multiple periods due to understated liabilities, impacting investor confidence.
• The company's management acknowledges material weaknesses in internal controls over financial reporting.
• Auditors express substantial doubt about Abpro's ability to continue as a going concern due to recurring losses and the need for additional funding.
• The company is in breach of its license agreement with MedImmune/AstraZeneca.

Risks

• The company's ability to raise additional capital is uncertain, raising substantial doubt about its ability to continue as a going concern.
• Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
• The company's product candidates are in early stages of development and have never been tested in a human subject.
• The company is in breach of the terms of its license agreement with MedImmune/AstraZeneca, which could lead to termination of the agreement.
• The company has identified material weaknesses in its internal control over financial reporting, which could affect its ability to ensure timely and reliable financial reports.
• The restatement of prior period financial statements may affect investor confidence and raise reputational issues.

Future Outlook

The company plans to raise additional capital through equity or debt financing to meet its operating cash needs and advance its preclinical and clinical development programs. They expect to initiate clinical trials for ABP-102 and ABP-201 in 2026.

Industry Context

The biotechnology and biopharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. The company faces competition from entities that have developed or may develop product candidates for the treatment of the diseases that it is initially targeting, including companies developing novel treatments and technology platforms.

Comparison to Industry Standards

• The document mentions competitors such as Amgen, Bristol-Myers Squibb Company, Janux, J&J, Genentech/Roche, Vir Bio and Xencor in the immune-based treatments for cancer.
• In ophthalmology, competitors include Allergan plc, Genentech/Roche, Novartis International AG, and Regeneron Pharmaceuticals, Inc.

Management Changes

Legal Proceedings

• The company is involved in a legal proceeding with a CRO vendor regarding unpaid installments under a settlement agreement.
• The company received a notice of breach and termination from MSK demanding payments totaling at least $1,060,405 in principal and $169,173 in interest.
• The company's landlord filed a Summary Process (Eviction) Summons and Complaint with the District Court in Woburn, Massachusetts relating to our Cummings Park premises.

Related Party Transactions

• The company entered into a promissory note agreement with ABI, a significant investor in the company.
• The company issued promissory notes to one of its executives and one of its directors for deferred bonuses.
• The company entered into a separate promissory note agreement with the same executive to receive additional funding.

Stakeholder Impact

• Shareholders may experience dilution in the future due to equity issuances.
• The market price of the company's common stock may decline.
• The company's failure to meet Nasdaq's continued listing requirements could result in a delisting of its shares.

Next Steps

• The company plans to initiate clinical trials for ABP-102 in the first half of 2026 and in the second half of 2026 for ABP-201.
• The company plans to raise additional capital through equity or debt financing to meet its operating cash needs.

Key Dates

Keywords

restatement, going concern, internal control, financial reporting, license agreement, clinical trials, ABP-102, ABP-201, Celltrion, Abpro Bio, SEPA, YA II PN, Convertible Note, MedImmune, AstraZeneca, biotechnology, pharmaceutical